Mode of action of triphasic oral contraception
作者： J. Spona , W. H. F. Schneider , U. Lachnit-Fixson
DOI: 10.1007/978-94-011-6666-9_4
关键词:
摘要: The present experiments were carried out to investigate the borderline dose for inhibition of ovulation by levonorgestrel and study mode action triphasic oral contraception. was found be 50 µg per day. In addition, bioavailability after daily administration 100 µg, respectively, recorded between 400 600 pg/ml serum. Daily ingestion 150 resulted in serum levels 1 ng/ml. Two different preparations a contraceptive studied. test composition: SH B 264 AB: six coated tablets containing 30 ethinyloestradiol 50µg levonorgestrel; five 40µg 75µg ten 125 levonorgestrel. 261 ug 40 Serum LH, 17β-oestradiol progesterone estimated radioimmunoassay women receiving either AB or AB. cervical score karyopyknotic index vaginal smear samples recorded. data investigation combine suggest that contraception acts inhibiting providing back-up mechanism reducing score. reduction oflevonorgestrel does not interfere with cycle control, since very precisely mimics endogenous sex hormone normal cycle. Thus, patterns endometrial hormone-receptor similar those cycles are expected. preparation this new generation contraceptives is well-balanced formulation greatest safety least side-effects possible.
springer.com
sci-hub.st 参考文章(22)
Carol Cleaves Korenbrot, Marian Cleeves Diamond, Hormonal contraceptives, estrogens, and human welfare Academic Press. ,(1978)
N.E. Miller, D.S. Thelle, O.H. Førde, O.D. Mjøs, The Tromso Heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. The Lancet. ,vol. 309, pp. 965- 968 ,(1977) , 10.1016/S0140-6736(77)92274-7
M. P. Vessey, R. Doll, A. S. Fairbairn, G. Glober, Postoperative Thromboembolism and the Use of Oral Contraceptives BMJ. ,vol. 3, pp. 123- 126 ,(1970) , 10.1136/BMJ.3.5715.123
Stephan Roössner, LOWERING OF H.D.L. CHOLESTEROL BY ORAL CONTRACEPTIVES The Lancet. ,vol. 312, pp. 269- ,(1978) , 10.1016/S0140-6736(78)91787-7
Valerie Beral, ORAL-CONTRACEPTIVES AND HEALTH The Lancet. ,vol. 303, pp. 1280- 1280 ,(1974) , 10.1016/S0140-6736(74)90024-5
G.J Miller, N.E Miller, PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE The Lancet. ,vol. 305, pp. 16- 19 ,(1975) , 10.1016/S0140-6736(75)92376-4
J. Spona, W. H. F. Schneider, Central and Peripheral Parameters of the Menstrual Cycle Under the Influence of a New Combined Oral Contraceptive Acta Obstetricia et Gynecologica Scandinavica. ,vol. 55, pp. 45- 50 ,(1976) , 10.3109/00016347609156448
J. Spona, R. Ulm, C. Bieglmayer, P. Husslein, Hormone serum levels and hormone receptor contents of endometria in women with normal menstrual cycles and patients bearing endometrial carcinoma. Gynecologic and Obstetric Investigation. ,vol. 10, pp. 71- 80 ,(1979) , 10.1159/000299920
J. Spona, E. Weiner, B. Nieuweboer, M. Hümpel, W.H.F. Schneider, E.D.B. Johansson, Injectable depot contraceptives on d-norgestrel basis II. Clinical pharmacokinetic studies with d-norgestrel undecylate in women Contraception. ,vol. 15, pp. 413- 428 ,(1977) , 10.1016/0010-7824(77)90004-X
U. Larsson-Cohn, L Wallentin, G. Zador, Plasma lipids and high density lipoproteins during oral contraception with different combinations of ethinyl estradiol and levonorgestrel. Hormone and Metabolic Research. ,vol. 11, pp. 437- 440 ,(1979) , 10.1055/S-0028-1092755